

SAFETY DATA SHEET

AVASTIN Vials 100 mg/4 ml

Version
1.5

Revision Date:
10-10-2022

Date of last issue: 01-30-2020
Date of first issue: 12-04-2015

SECTION 1. IDENTIFICATION

Product name : AVASTIN Vials 100 mg/4 ml

Product code : RO487-6646/F01

Manufacturer or supplier's details

Company name of supplier : Genentech, Inc.

Address : 1 DNA Way
South San Francisco, CA 94080
USA

Telephone : 001-(650) 225-1000

E-mail address : info.sds@roche.com

Emergency telephone

Emergency telephone number : US Chemtrec phone (800)-424-9300

Recommended use of the chemical and restrictions on use

Recommended use : Formulated pharmaceutical active substance

Restrictions on use : For professional users only.

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Not a hazardous substance or mixture.

GHS label elements

Not a hazardous substance or mixture.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Bevacizumab	216974-75-3	2.5
Trehalose (D+)-, 2H ₂ O	6138-23-4	6.0
Sodium phosphate, monobasic, monohydrate	10049-21-5	0.58
Phosphoric acid, sodium salt (1:2)	7558-79-4	0.12
Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.	9005-64-5	0.04
Water	7732-18-5	> 90.0

AVASTIN Vials 100 mg/4 ml

Version
1.5

Revision Date:
10-10-2022

Date of last issue: 01-30-2020
Date of first issue: 12-04-2015

SECTION 4. FIRST AID MEASURES

- General advice : Do not leave the victim unattended.
- If inhaled : Move to fresh air.
If unconscious, place in recovery position and seek medical advice.
If symptoms persist, call a physician.
- In case of skin contact : If on skin, rinse well with water.
- In case of eye contact : Immediately flush eye(s) with plenty of water.
Remove contact lenses.
Protect unharmed eye.
If eye irritation persists, consult a specialist.
- If swallowed : Keep respiratory tract clear.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.
Rinse mouth with water.
- Most important symptoms and effects, both acute and delayed : None known.
- Notes to physician : The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Specific hazards during fire fighting : No information available.
- Hazardous combustion products : Carbon oxides
In case of fire hazardous decomposition products may be produced such as:
Nitrogen oxides (NOx)
- Further information : Standard procedure for chemical fires.
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protection : Refer to protective measures listed in sections 7 and 8.

AVASTIN Vials 100 mg/4 ml

Version
1.5

Revision Date:
10-10-2022

Date of last issue: 01-30-2020
Date of first issue: 12-04-2015

tive equipment and emergency procedures

Environmental precautions : Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Wipe up with absorbent material (e.g. cloth, fleece).
Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion : Normal measures for preventive fire protection.

Advice on safe handling : For personal protection see section 8.
Smoking, eating and drinking should be prohibited in the application area.

Conditions for safe storage : Electrical installations / working materials must comply with the technological safety standards.

Further information on storage conditions : See label, package insert or internal guidelines

Materials to avoid : No materials to be especially mentioned.

Storage temperature : Protected from heat and light

Further information on storage stability : No decomposition if stored and applied as directed.

Packaging material : Suitable material: Stainless steel, glass

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Bevacizumab	216974-75-3	IOEL	0.05 mg/m3	Roche Industrial Hygiene Committee (RIHC)

Engineering measures : No data available

Personal protective equipment

Respiratory protection : No personal respiratory protective equipment normally required.

Hand protection

In case of contact through splashing:

AVASTIN Vials 100 mg/4 mlVersion
1.5Revision Date:
10-10-2022Date of last issue: 01-30-2020
Date of first issue: 12-04-2015

Material : Nitrile rubber
Break through time : > 30 min
Glove thickness : > 0.11 mm

In case of full contact:
Material : butyl-rubber
Break through time : > 480 min
Glove thickness : > 0.4 mm

Remarks : Wear appropriate protective gloves to prevent skin contact.
Replace torn or punctured gloves promptly.
Eye protection : Safety glasses
Skin and body protection : Protective suit
Hygiene measures : Handle in accordance with good industrial hygiene and safety practice.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution, Clear liquid, Sterile liquid

Color : colorless

Odor : No data available

Odor Threshold : No data available

pH : 5.9 - 6.3

Melting point/range : No data available

Boiling point/boiling range : ca. 212 °F / 100 °C

Flash point : does not flash

Evaporation rate : No data available

Self-ignition : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

SAFETY DATA SHEET

AVASTIN Vials 100 mg/4 ml

Version
1.5

Revision Date:
10-10-2022

Date of last issue: 01-30-2020
Date of first issue: 12-04-2015

Relative density	:	No data available
Density	:	1.031 g/cm ³
Solubility(ies)		
Water solubility	:	completely miscible
Solubility in other solvents	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	No dangerous reaction known under conditions of normal use.
Chemical stability	:	Stable under normal conditions. Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created Does not contain any antimicrobial preservative; therefore, care must be taken to ensure the sterility of the prepared solution
Possibility of hazardous reactions	:	Stable under recommended storage conditions. No hazards to be specially mentioned.
Conditions to avoid	:	Exposure to light.
Incompatible materials	:	No data available
Hazardous decomposition products	:	No data available

SECTION 11. TOXICOLOGICAL INFORMATION

Acute toxicity

Not classified based on available information.

Components:

Trehalose (D+)-, 2H₂O:

Acute oral toxicity : LD50 (Rat): 16,000 mg/kg

AVASTIN Vials 100 mg/4 ml

Version
1.5

Revision Date:
10-10-2022

Date of last issue: 01-30-2020
Date of first issue: 12-04-2015

Bevacizumab:

Acute oral toxicity : Remarks: Not bioavailable by oral administration

Acute toxicity (other routes of administration) : No-observed-effect level (cynomolgus monkey): 50 mg/kg
Application Route: i.v.

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Carcinogenicity

Not classified based on available information.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:

Bevacizumab:

Effects on fetal development : Species: Rabbit
Application Route: i.v.
Result: Teratogenic effects., Embryotoxic effects.

Species: Humans
Application Route: i.v.
Result: Critical exposure in human after parenteral administration only, Parenteral administration to pregnant women can cause fetal harm

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

AVASTIN Vials 100 mg/4 mlVersion
1.5Revision Date:
10-10-2022Date of last issue: 01-30-2020
Date of first issue: 12-04-2015**Repeated dose toxicity****Components:****Bevacizumab:**

Species : cynomolgus monkey
 LOAEL : 2 mg/kg/w
 Application Route : i.v.
 Exposure time : 26 Weeks
 Remarks : Subchronic toxicity

Aspiration toxicity

Not classified based on available information.

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Trehalose (D+)-, 2H₂O:**

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 100 mg/l
 Exposure time: 96 h
 Test Type: static test

Toxicity to fish (Chronic toxicity) : NOEC (Danio rerio (zebra fish)): 100 mg/l
 Exposure time: 96 d

Ecotoxicology Assessment

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

Bevacizumab:

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
 Exposure time: 48 h
 Method: OECD Test Guideline 202
 GLP: no

NOEC (Daphnia magna (Water flea)): 100 mg/l
 Exposure time: 48 h
 Method: OECD Test Guideline 202
 GLP: no

Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): > 100 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201
 GLP: no

AVASTIN Vials 100 mg/4 mlVersion
1.5Revision Date:
10-10-2022Date of last issue: 01-30-2020
Date of first issue: 12-04-2015

EyC50 (Desmodesmus subspicatus (green algae)): ca. 100 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

GLP: no

NOEC (Desmodesmus subspicatus (green algae)): < 100 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

GLP: no

Toxicity to microorganisms : (activated sludge): 100 mg/l
 Exposure time: 14 d
 Method: OECD Test Guideline 301F
 GLP: no
 Remarks: no adverse influence on substrate biodegradation

Persistence and degradability**Components:****Trehalose (D+)-, 2H₂O:**

Biodegradability : aerobic
 Inoculum: activated sludge, non-adapted
 Biochemical oxygen demand
 Result: Readily biodegradable.
 Biodegradation: 73 %
 Method: OECD Test Guideline 301A
 Remarks: The 10 day time window criterion is not fulfilled.

aerobic
 Inoculum: activated sludge, non-adapted
 Dissolved organic carbon (DOC)
 Result: Readily biodegradable.
 Biodegradation: 98 %
 Method: OECD Test Guideline 301A

Bevacizumab:

Biodegradability : Result: Globular proteins are generally well biodegradable

Concentration: 100 mg/l
 Theoretical oxygen demand
 Result: Readily biodegradable.
 Biodegradation: 78 %
 Exposure time: 28 d
 Method: OECD Test Guideline 301F
 GLP: no

Concentration: 100 mg/l
 Dissolved organic carbon (DOC)
 Result: Readily biodegradable.
 Biodegradation: 96 %
 Exposure time: 28 d
 Method: OECD Test Guideline 301F
 GLP: no

AVASTIN Vials 100 mg/4 ml

Version
1.5

Revision Date:
10-10-2022

Date of last issue: 01-30-2020
Date of first issue: 12-04-2015

Bioaccumulative potential

Components:

Trehalose (D+)-, 2H2O:

Partition coefficient: n-octanol/water : Remarks: No data available

Bevacizumab:

Partition coefficient: n-octanol/water : Remarks: No data available

Mobility in soil

No data available

Other adverse effects

Product:

Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

Components:

Bevacizumab:

Additional ecological information : Monoclonal antibodies are proteins with highly specific affinity to a certain antigen; therefore, no appreciable ecotoxic potential is to be expected

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Can be disposed as waste water, when in compliance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
Do not re-use empty containers.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

AVASTIN Vials 100 mg/4 mlVersion
1.5Revision Date:
10-10-2022Date of last issue: 01-30-2020
Date of first issue: 12-04-2015

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable

Domestic regulation**49 CFR**

Not regulated as a dangerous good

Special precautions for userRemarks : Not dangerous goods in the meaning of ADR/RID, ADN,
IMDG-Code, ICAO/IATA-DGR**SECTION 15. REGULATORY INFORMATION****CERCLA Reportable Quantity**

Listed substances in the product are at low enough levels to not be expected to exceed the RQ

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : No SARA Hazards**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.**Clean Air Act**

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act

The following Hazardous Substances are listed under the U.S. CleanWater Act, Section 311, Table 116.4A:

Phosphoric acid, sodium 7558-79-4 >= 0.1 - < 1 %
salt (1:2)

The following Hazardous Chemicals are listed under the U.S. CleanWater Act, Section 311, Table 117.3:

Phosphoric acid, sodium 7558-79-4 >= 0.1 - < 1 %
salt (1:2)

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

AVASTIN Vials 100 mg/4 ml

Version
1.5

Revision Date:
10-10-2022

Date of last issue: 01-30-2020
Date of first issue: 12-04-2015

US State Regulations

Massachusetts Right To Know

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know

Water	7732-18-5
Trehalose (D+)-, 2H ₂ O	6138-23-4
Phosphoric acid, sodium salt (1:2)	7558-79-4

Maine Chemicals of High Concern

Product does not contain any listed chemicals

Vermont Chemicals of High Concern

Product does not contain any listed chemicals

Washington Chemicals of High Concern

Product does not contain any listed chemicals

California Prop. 65

WARNING: This product can expose you to chemicals including Bevacizumab, which is/are known to the State of California to cause birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.

The ingredients of this product are reported in the following inventories:

AIIC	: Not in compliance with the inventory
DSL	: This product contains the following components that are not on the Canadian DSL nor NDSL. Bevacizumab
NZIoC	: On the inventory, or in compliance with the inventory
ENCS	: Not in compliance with the inventory
ISHL	: Not in compliance with the inventory
KECI	: Not in compliance with the inventory
PICCS	: Not in compliance with the inventory
IECSC	: Not in compliance with the inventory
TCSI	: Not in compliance with the inventory
TSCA	: Product contains substance(s) not listed on TSCA inventory.
TECI	: Not in compliance with the inventory

TSCA list

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

AVASTIN Vials 100 mg/4 ml


Version
1.5

Revision Date:
10-10-2022

Date of last issue: 01-30-2020
Date of first issue: 12-04-2015

SECTION 16. OTHER INFORMATION

NFPA 704:



HMIS® IV:

HEALTH	/	0
FLAMMABILITY		0
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act

SAFETY DATA SHEET

AVASTIN Vials 100 mg/4 ml

Version
1.5

Revision Date:
10-10-2022

Date of last issue: 01-30-2020
Date of first issue: 12-04-2015

(United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 10-10-2022

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 2104